mRNA medicines represent the genesis of a fourth pillar of pharma innovation. While exciting, there are several critical challenges we must solve to strengthen this pillar, including stability and deliverability.
- Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
- NK Cell Therapies: How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach
- Improving Governance And Compliance With Knowledge Management
- China’s Rising Role On The Global Stage In The Oncology Market
- GMP Plant Uniform Lockers And Procedures: Best Practices
- A Deeper Look At What's Driving Dependence On Biotech Contract Manufacturers
- Developing A Process Performance Qualification Master Plan For Gene Therapies
- What Time Is Best To Bring My CDMO On Board?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Rare Disease – 2018-2022 Global Clinical Trial Landscape
Discover why the collaboration and expertise of organizations are vital in advancing rare disease research and improving the lives of millions affected.
-
Pursuing Breakthrough Therapies For Rare Metabolic Diseases
Discover how Veristat’s full-service clinical trial team helped tightly coordinate a gene therapy's dosing administration and data review.
-
Expansion Of MDCK Cells On Microcarriers Via Growth In Stirred Vessels
We demonstrate how microcarriers provide an ideal substrate for expansion of MDCK cells in closed stirred-vessel systems and lay the groundwork for subsequent developmental studies in larger bioreactor formats.
-
Remote Access And Monitoring Of Bioprocess Unit Operations
Digital transformation projects require a scalable connectivity solution for the manufacturing floor that is easily and rapidly deployed. Explore elements that enable connectivity among equipment.
-
Achieve Manufacturing Scale For Your Viral Vector Production
Elevate your viral vector production to commercial scale by choosing the optimal production system paired with the right single-use bioreactor combination.
-
Efficient, Large-Scale Transfection Of T-Cells Using Flowfect® Technology
The objective of this study was to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post-transfection growth using Kytopen’s Flowfect® technology.
-
Testing The Transduction Of AAV-Based Therapeutics
Organ-on-a-Chip technology has emerged as a solution to the limitations of conventional preclinical models. Learn how Liver-Chips can be used to test the delivery efficiency and safety of AAV vectors.
-
RNA: The Next Era In Therapeutic Development
Review the unique set of challenges for RNA production that must be considered and solved to reach their full therapeutic potential.
-
Assessing Liquid Transfer Performance With Reliable, Ready-To-Use Reagents
See how specially formulated dye-containing solutions replicate the liquid transfer properties of several commercially available PCR master mixes, making them reliable and ready-to-use reagents for determining liquid transfer performance.
-
A Comprehensive Planning Approach For Cancer Antibody
Discover how a clinical-stage biotech company was able to accelerate pathways for development and regulatory review of their first Phase I protocol for an immuno-oncology antibody.
NEWSLETTER ARCHIVE
- 04.25.24 -- Insights From Across The Globe: Trends In Clinical Trials
- 04.25.24 -- Reducing The Disease Burden Of AML With Vor Bio's Dr. Robert Ang
- 04.24.24 -- Outsourcing Best Practices To Increase Efficiency And Compliance
- 04.24.24 -- Cell Counting Is Growing More Important Amid Advanced Therapy's Rise
- 04.23.24 -- Inside Tenaya Therapeutics' AAV9-Based Gene Therapy
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections